[Activity of matrix metalloproteinases MMP-2 and MMP-9 in bone marrow plasma of patients with acute myeloid leukemia].
Prognostic significance of the ratio of MMP-2 and MMP-9 activities (MMP-2/MMP-9) have been investigated in bone marrow plasma (BMP) of 53 patients with acute myeloid leukemia (AML) using the method of zymography. During BMP collection 33 patients were diagnosed with complete remission (CR) and 22 patients without CR. The ratio MMP-2/MMP-9 was approximately 1.00 (the upper limit was equal 1.77) in the 75% of patients. At the same time the ratio was more than 3 times higher in 13 patients (25%): their minimal value was 1.80 (p < 0.001). In the group with high ratio MMP-2/MMP-9 only 3 patients were with CR, and 10 patients with resistant variant of AML. The median of the overall survival (OS) of these 10 patients was significantly lower than OS of other investigated AML patients (7.0 vs 33.5 months p < 0.001). Thus the high MMP-2/MMP-9 ratio (> or = 1.8) may be associated with unfavorable course of AML.
I F
IF
Lesnichenko
S V
SV
Gritsaev
A N
AN
Sergeev
I I
II
Kostroma
S A
SA
Tiranova
D000293:Adolescent; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001853:Bone Marrow / Q000378:metabolism* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000378:metabolism / Q000401:mortality / Q000473:pathology / Q000628:therapy; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism*; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D008875:Middle Aged; D015996:Survival Rate
D014408:Biomarkers, Tumor; C522361:MMP2 protein, human; D020778:Matrix Metalloproteinase 2; C579270:MMP9 protein, human; D020780:Matrix Metalloproteinase 9